ATE276255T1 - Tetracyclische azepinoindol verbindungen als 5-ht rezeptor liganden - Google Patents

Tetracyclische azepinoindol verbindungen als 5-ht rezeptor liganden

Info

Publication number
ATE276255T1
ATE276255T1 AT00923532T AT00923532T ATE276255T1 AT E276255 T1 ATE276255 T1 AT E276255T1 AT 00923532 T AT00923532 T AT 00923532T AT 00923532 T AT00923532 T AT 00923532T AT E276255 T1 ATE276255 T1 AT E276255T1
Authority
AT
Austria
Prior art keywords
azepinoindole
tetracyclic
compounds
receptor ligands
ligands
Prior art date
Application number
AT00923532T
Other languages
English (en)
Inventor
Jackson B Hester Jr
Bruce N Rogers
E Jon Jacobsen
Michael Dalton Ennis
Brad A Acker
Velde Susan L Vander
Kristine E Frank
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE276255T1 publication Critical patent/ATE276255T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/16Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT00923532T 1999-04-23 2000-04-20 Tetracyclische azepinoindol verbindungen als 5-ht rezeptor liganden ATE276255T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13081199P 1999-04-23 1999-04-23
PCT/US2000/010600 WO2000064899A1 (en) 1999-04-23 2000-04-20 Tetracyclic azepinoindole compounds as 5-ht receptor ligands

Publications (1)

Publication Number Publication Date
ATE276255T1 true ATE276255T1 (de) 2004-10-15

Family

ID=22446459

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00923532T ATE276255T1 (de) 1999-04-23 2000-04-20 Tetracyclische azepinoindol verbindungen als 5-ht rezeptor liganden

Country Status (20)

Country Link
EP (1) EP1173440B1 (de)
JP (1) JP2002543080A (de)
KR (1) KR20020005708A (de)
CN (1) CN1183132C (de)
AR (1) AR023574A1 (de)
AT (1) ATE276255T1 (de)
AU (1) AU760943C (de)
BR (1) BR0009983A (de)
CA (1) CA2367682A1 (de)
DE (1) DE60013803T2 (de)
DK (1) DK1173440T3 (de)
EC (1) ECSP003426A (de)
ES (1) ES2226822T3 (de)
HK (1) HK1045512B (de)
NZ (1) NZ514553A (de)
PE (1) PE20010052A1 (de)
PT (1) PT1173440E (de)
SI (1) SI1173440T1 (de)
WO (1) WO2000064899A1 (de)
ZA (1) ZA200108636B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01012914A (es) 1999-06-15 2004-04-21 Bristol Myers Squibb Co Gama-carbolinas fundidas de heterociclo substituido.
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
AU2001269781A1 (en) 2000-07-06 2002-01-21 Pharmacia And Upjohn Company Substituted 2,3,7,8,9,10,11,12-octahydroazepino(4,5-b)pyrano(3,2-e) indoles
AR035493A1 (es) 2000-09-20 2004-06-02 Upjohn Co Derivados de azepino (4,5b) indolina sustituidos, composicion farmaceutica y el uso de dichos derivados para preparar un medicamento
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
MXPA03005438A (es) * 2000-12-20 2004-05-05 Bristol Myers Squibb Co Pirioindoles substituidos como agonistas y antagonistas de serotonina.
US20020160999A1 (en) * 2001-01-08 2002-10-31 Jacobsen Susan Fox Substituted indolines
JP2005501092A (ja) * 2001-08-06 2005-01-13 ファルマシア・アンド・アップジョン・カンパニー 治療上有用な四環リガンド
US20030060462A1 (en) * 2001-08-06 2003-03-27 Hoffman Robert L. Therapeutic compounds
US6887868B2 (en) 2001-09-21 2005-05-03 Pharmacia & Upjohn Company Therapeutic 5-HT ligand compounds
JP2005508969A (ja) * 2001-10-18 2005-04-07 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 5−ht活性を有するテトラサイクリックアザインドールおよびインドリン
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
MX2008009178A (es) * 2006-01-19 2008-12-05 Athersys Inc Tiofenil y pirrolil acepinas como ligandos del receptor de serotonina 5-ht2c y sus usos.
EP2018863B9 (de) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Kondensierte, heterocyclische Verbindung und ihre Verwendung
CN101796051B (zh) 2007-03-12 2013-11-06 细胞内治疗公司 与取代的杂环稠合的γ-咔啉的合成
EP2789338A3 (de) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Kondensiertes Pyridinderivat und seine Verwendung
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
WO2010124042A2 (en) * 2009-04-23 2010-10-28 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
EP2836211B1 (de) 2012-04-14 2019-03-20 Intra-Cellular Therapies, Inc. Behandlung von PTSD und Impulskontrollestörung
PT2968320T (pt) 2013-03-15 2021-01-28 Intra Cellular Therapies Inc Compostos orgânicos
IL321987A (en) 2013-12-03 2025-09-01 Intra Cellular Therapies Inc A long-acting injectable preparation containing polymeric microspheres of modified compressed gamma-carboline heterocyclic compounds or a sustained-release pharmaceutical preparation containing these compounds for use in the treatment of bipolar I and/or bipolar II disorders
CN106456638A (zh) 2014-04-04 2017-02-22 细胞内治疗公司 有机化合物
WO2015154025A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
CA3011983A1 (en) 2016-01-26 2017-08-03 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規塩類および結晶
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
JP6997718B2 (ja) 2016-03-28 2022-01-18 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規共結晶
CN105837571A (zh) * 2016-04-23 2016-08-10 何华琼 盐酸倍他司汀的药物组合物及其在生物医药中的应用
US12343337B2 (en) 2016-09-29 2025-07-01 The Regents Of The University Of California Compounds for increasing neural plasticity
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018175969A1 (en) 2017-03-24 2018-09-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
IL272252B2 (en) 2017-07-26 2024-03-01 Intra Cellular Therapies Inc Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment
KR102899502B1 (ko) 2017-07-26 2025-12-11 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
MX2020009928A (es) 2018-03-23 2021-01-08 Intra Cellular Therapies Inc Compuestos organicos.
EP3628007B1 (de) 2018-06-06 2023-05-03 Intra-Cellular Therapies, Inc. Neuartige salze und kristalle
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
EP3609891B1 (de) 2018-06-11 2026-02-11 Intra-Cellular Therapies, Inc. Synthese kondensierter gamma-carboline mit substituiertem heterozyklus
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
KR20210052472A (ko) 2018-08-31 2021-05-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
WO2020047407A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
KR102901722B1 (ko) 2018-12-17 2025-12-17 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로사이클 융합 감마-카르볼린 합성
AU2019403149B2 (en) 2018-12-17 2025-04-03 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
BR112022000231A2 (pt) 2019-07-07 2022-02-22 Intra Cellular Therapies Inc Novos métodos
JP7261942B2 (ja) 2019-12-11 2023-04-20 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
KR20240150417A (ko) * 2021-12-15 2024-10-15 델릭스 테라퓨틱스, 인크. 페녹시 및 벤질옥시로 치환된 사이코플라스토겐 및 그의 용도
EP4448532A4 (de) * 2021-12-15 2025-12-24 Delix Therapeutics Inc Kondensierte pyrrolidin-psycoplastigene und verwendungen davon
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839357A (en) * 1966-05-10 1974-10-01 Upjohn Co 1,2,3,4,5,6-hexahydroazepino(4,5-b)indoles
US3676558A (en) * 1970-08-28 1972-07-11 Upjohn Co Anorexigenic compositions comprising 6-alkyl-1,2,3,4,5,6-hexahydroazepino 4,5-indoles as active ingredient and process of treatment
EP0377238A1 (de) * 1988-12-22 1990-07-11 Duphar International Research B.V Annelierte Indolo(3,2-c)-lactame

Also Published As

Publication number Publication date
DK1173440T3 (da) 2004-12-20
EP1173440A1 (de) 2002-01-23
CA2367682A1 (en) 2000-11-02
AU760943C (en) 2003-12-04
NZ514553A (en) 2003-10-31
AR023574A1 (es) 2002-09-04
CN1348454A (zh) 2002-05-08
PE20010052A1 (es) 2001-01-27
SI1173440T1 (en) 2005-02-28
PT1173440E (pt) 2004-12-31
AU760943B2 (en) 2003-05-22
ECSP003426A (es) 2000-10-24
HK1045512A1 (en) 2004-10-15
EP1173440B1 (de) 2004-09-15
DE60013803T2 (de) 2005-11-17
ZA200108636B (en) 2003-02-19
AU4363700A (en) 2000-11-10
WO2000064899A1 (en) 2000-11-02
ES2226822T3 (es) 2005-04-01
HK1045512B (zh) 2005-09-02
KR20020005708A (ko) 2002-01-17
JP2002543080A (ja) 2002-12-17
CN1183132C (zh) 2005-01-05
BR0009983A (pt) 2002-04-16
DE60013803D1 (de) 2004-10-21

Similar Documents

Publication Publication Date Title
ATE276255T1 (de) Tetracyclische azepinoindol verbindungen als 5-ht rezeptor liganden
ATE253067T1 (de) Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden
DE60021262D1 (de) Bizyklische heteroaromatische verbindungen als lh-agonisten
DE60129746D1 (de) Hetorocyclindazole und -azaindazole verbindungen als 5-hydroxytryptamine-6 liganden
DE60112064D1 (de) Benzoamid-piperidin verbindungen als substanz p-antagonisten
MA25403A1 (fr) Ligandes de recepteur de melanocortine
EE200200082A (et) Uued spiroühendid
DE60031481T8 (de) Polymer-gebundene funktionelle Verbindungen
IL154310A0 (en) Heterocyclic compounds as ligands of the gabaa receptor
ATE327988T1 (de) Chemokine rezeptor bindende heterozyklische verbindungen
PT1198453E (pt) Derivados de n-(indolcarbonil)-piperazina como ligandos do receptor 5-ht2a
ATE277933T1 (de) Thiophenverbindungen zur verwendung als antikrebsmittel
DE69903953D1 (de) 2-substituierte-1-piperidyl-benzimidazolverbindungen als orl1 rezeptor agonisten
ATE283845T1 (de) Pyrimidinon verbindungen
ATE283857T1 (de) Imidazo(1,5-aöpyrimido)5,4-döbenz azepinderivate als gaba-a-rezeptormodulatoren
DE60206652D1 (de) Benzothiazolderivate als adenosin-rezeptor-liganden
DE69819903D1 (de) Bizyklische verbindungen als liganden der 5-ht1 rezeptoren
ATE529419T1 (de) Chromanderivate als estrogene verbindungen
ATE311377T1 (de) Spirocyclische dopaminrezeptor-subtyp-liganden
ATE281456T1 (de) Aminotriazolopyridinderivate als adenosinrezeptorliganden
ATE321764T1 (de) Tetracyclische heteroverbindungen als modulatoren des östrogenrezeptors
DE60003045D1 (de) Heterozyclische verbindungen als angiogenese inhibitoren
DK1221445T3 (da) Pentacykliske taxanforbindelser
ATE280161T1 (de) Imidazolverbindungen als alpha2-adrenorezeptoren antagonisten
DE60012953D1 (de) 3-amino-2-phenylpiperidinderivate als substanz p antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1173440

Country of ref document: EP

REN Ceased due to non-payment of the annual fee